Globus Medical

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Globus Medical achieves record revenue, plans NuVasive merger

Globus Medical (GMED) delivered strong financial performance in 2022, with record revenue and notable growth across key segments.
The planned merger with NuVasive and focus on product innovation position the company for future success and market leadership.
Challenges such as retaining talent and addressing international market dynamics require strategic solutions for sustained growth.
Opportunities lie in diversifying revenue streams, expanding product offerings, and leveraging international markets for continued success.

Globus Medical (GMED) reports record Q1 sales, eyes growth opportunities

Globus Medical (GMED) delivered a strong Q1 performance with record sales and profit growth, driven by strategic initiatives and market demand. While facing challenges like merger delays and potential competition, the company's focus on innovation, technology leadership, and market recognition positions it well for sustained growth and success.

Globus Medical posts record Q2 sales, eyes growth through innovation

Globus Medical delivered a strong Q2 performance with record sales and profitability, driven by innovation and market expansion.
While facing integration challenges post-merger, the company's focus on growth segments and product innovation positions it well for future success.
Opportunities lie in expanding market presence, driving innovation, and capitalizing on technological advancements to sustain growth momentum.

Globus Medical reports record Q3 sales, eyes growth opportunities

Globus Medical's Q3 performance reflects robust sales growth, steady EPS, and progress towards revenue targets, underpinned by innovative product launches and strategic integration efforts.
While facing challenges in hiring and cost synergies, the company's focus on talent acquisition, cost management, and segment-specific strategies positions them well for future growth.
Opportunities lie in new product launches, technological advancements, and streamlined operations through sales force integration, indicating a promising trajectory for Globus Medical's continued success.

Globus Medical (GMED) reports record revenue in 2023, eyes growth amid challenges

Globus Medical (GMED) delivered strong financial results in 2023, driven by the NuVasive merger, with a focus on integration and innovation. While facing challenges from dissynergies and market competition, GMED is poised to capitalize on growth opportunities through strategic initiatives and product launches.

Globus Medical excels in Q1 2024, eyes Enabling Technologies growth

Globus Medical's Q1 2024 showcased exceptional sales growth, margin improvement, and strategic initiatives. Despite challenges in integration and product rollout timing, the company is poised for long-term success. Opportunities in Enabling Technologies and cost leverage position Globus for continued growth.

Globus Medical excels in Q3, eyes margin improvement strategies

Globus Medical's Q3 performance reflects strong financial results, innovation, and market expansion. While challenges in margin improvement persist, the company's strategic focus on cost optimization and product development sets the stage for continued growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

GMED ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Globus Medical, Inc. Shareholders Who Lost Money

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. (“Globus Medical” or “the Company”) (NYSE: GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

Globus Medical, Inc. (GMED) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or "the Company") (NYSE:GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Potentially Illegal Actions By Globus Medical Inc And Investors Are Urged To Reach Out

NEW YORK CITY, NY / ACCESSWIRE / August 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Shareholders to Contact the Firm Today!

NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

Globus Medical, Inc. (GMED) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or "the Company") (NYSE:GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into Globus Medical Inc For Possible Securities Fraud

NEW YORK CITY, NY / ACCESSWIRE / August 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Investors to Contact the Firm Today!

NEW YORK, NY / ACCESSWIRE / August 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

Globus Medical, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - GMED

Shareholder Rights Advocates at Levi & Korsinsky Investigate Globus Medical, Inc. (GMED) Regarding Possible Securities Fraud Violations

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or "the Company") (NYSE:GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Globus Medical Inc Is Being Investigated By The Schall Law Firm For Potential Securities Law Violations And Investors Should Participate

NEW YORK CITY, NY / ACCESSWIRE / August 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Investors to Contact the Firm Today!

NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Globus Medical, Inc. (GMED)

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or "the Company") (NYSE:GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Possible Securities Fraud By Globus Medical Inc. And Stockholders Are Urged To Reach Out

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or "the Company") (NYSE:GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Globus Medical Inc. Is Being Investigated By The Schall Law Firm For Potential Securities Laws Violations And Investors Are Invited To Join

NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

GMED ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Globus Medical, Inc. Investment

NEW YORK CITY, NY / ACCESSWIRE / August 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Investors to Contact the Firm Today!

Globus Medical, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - GMED

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

GMED ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Globus Medical, Inc.

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or "the Company") (NYSE:GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Globus Medical Inc. Investors To Lead A Securities Fraud Investigation

Lost Money on Globus Medical, Inc. (GMED)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK CITY, NY / ACCESSWIRE / August 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.

GMED SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Stockholders to Contact the Firm!

Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.

Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or "the Company") (NYSE:GMED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders In Globus Medical Inc. Are Encouraged To Participate In A Securities Fraud Investigation With The Schall Law Firm

AUDUBON, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ADIRA™ XLIF™ Plate System, the Company's first product launch compatible across its expanded lateral interbody portfolio.

Globus Medical Launches ADIRA™ XLIF™ Plate System

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.

News for Globus Medical Stock (GMED)